Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2004

01-05-2004 | Article

Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes.

The Finnish Diabetes Prevention Study

Authors: O. Laukkanen, J. Pihlajamäki, J. Lindström, J. Eriksson, T. T. Valle, H. Hämäläinen, P. Ilanne-Parikka, S. Keinänen-Kiukaanniemi, J. Tuomilehto, M. Uusitupa, M. Laakso, for the Finnish Diabetes Prevention Study Group

Published in: Diabetologia | Issue 5/2004

Login to get access

Abstract

Aims/hypothesis

Type 2 diabetes is a complex disorder with strong heritability. The aim of our study was to investigate whether common polymorphisms in the genes regulating the early insulin signalling pathway (insulin; A-23T, insulin-like growth factor 1 receptor [IGF-1R]; GAG1013GAA, plasma cell membrane glycoprotein 1 [PC-1]; K121Q, insulin receptor substrate [IRS-1]; G972R, insulin receptor substrate 2 [IRS-2]; G1057D and phosphatidylinositol 3-kinase p85α [PI3K]; M326I) affect the weight change and development of Type 2 diabetes in the Finnish Diabetes Prevention Study.

Methods

We screened for the polymorphisms in 490 overweight subjects with impaired glucose tolerance whose DNA was available from the Finnish Diabetes Prevention Study. These subjects were randomly allocated into a control group and an intervention group characterised by intensive, individualised diet and exercise.

Results

In carriers of the GAA1013GAA genotype of IGF-1R, the R972 allele of IRS-1 and the D1057D genotype of IRS-2, lifestyle intervention did not lead to significant differences in weight loss between the intervention and control groups, implying a role of these risk genotypes in the regulation of body weight. We observed a statistically significant difference in the conversion rate from IGT to diabetes between the genotypes of the IGF-1R gene (GAG1013GAG: 18.6%, GAG1013GAA: 10.4%, GAA1013GAA: 19.5%, p=0.033). Common polymorporphisms in the insulin, PC-1 and PI3K genes did not regulate weight change or conversion to diabetes.

Conclusions/interpretation

The common polymorphisms of the IGF-1R, IRS-1 and IRS-2 genes may modify the weight change response to a lifestyle intervention but not the conversion from IGT to Type 2 diabetes, whereas IGF-1R may also regulate the risk of developing Type 2 diabetes.
Literature
1.
Groop LC (1997) The molecular genetics of non-insulin-dependent diabetes mellitus. J Intern Med 241:95–101CrossRefPubMed
2.
Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed
3.
Pan XR, Li GW, Hu YH et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544PubMed
4.
Weedon MN, Schwarz PE, Horikawa Y et al. (2003) Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am J Hum Genet 73:1208–1212CrossRefPubMed
5.
Altshuler D, Hirschorn JN, Klannemark M et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMed
6.
Gloyn AL, Weedon MN, Owen KR et al. (2003) Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52:568–572
7.
Saltiel AR, Pessin JE (2002) Insulin signaling pathways in time and space. Trends Cell Biol 12:65–71CrossRefPubMed
8.
Ong KK, Phillips DI, Fall C et al. (1999) The insulin gene VNTR, type 2 diabetes and birth weight. Nat Genet 21:262–263PubMed
9.
Le Stunff C, Fallin D, Schork NJ, Bougnères P (2000) The insulin gene VNTR is associated with fasting insulin levels and development of juvenile obesity. Nat Genet 26:444–446CrossRefPubMed
10.
Maddux BA, Goldfine ID (2000) Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes 49:13–19PubMed
11.
Frittitta L, Baratta R, Spampinato D et al. (2001) The Q121 PC-1 variant and obesity have additive and independent effects in causing insulin resistance. J Clin Endocrinol Metab 86:5888–5891PubMed
12.
Pizzuti A, Frittitta L, Argiolas A et al. (1999) A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 48:1881–1884PubMed
13.
Burks DJ, White MF (2001) IRS proteins and beta-cell function. Diabetes 50 [Suppl 1]:S140–S145
14.
Withers DJ, Gutierrez JS, Towery H et al. (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900–904PubMed
15.
Almind K, Frederiksen SK, Bernal D et al. (1999) Search for variants of the gene-promoter and the potential phosphotyrosine encoding sequence of the insulin receptor substrate-2 gene: evaluation of their relation with alterations in insulin secretion and insulin sensitivity. Diabetologia 42:1244–1249CrossRefPubMed
16.
Mammarella S, Romano F, Di Valerio A et al. (2000) Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes. Hum Mol Genet 9:2517–2521CrossRefPubMed
17.
Fritsche A, Madaus A, Renn W et al. (2001) The prevalent Gly1057Asp polymorphism in the insulin receptor substrate-2 gene is not associated with impaired insulin secretion. J Clin Endocrinol Metab 86:4822–4825
18.
Stefan N, Kovacs P, Stumvoll M et al. (2003) Metabolic effects of the Gly1057Asp polymorphism in IRS-2 and interactions with obesity. Diabetes 52:1544–1550
19.
Almind K, Bjørbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O (1993) Amino acid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 342:828–832PubMed
20.
Sigal RJ, Doria A, Warram JH, Krolewski AS (1996) Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:1657–1659
21.
Almind K, Inoue G, Pedersen O, Kahn CR (1996) A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 97:2569–2575PubMed
22.
Porzio O, Federici M, Hribal ML et al. (1999) The Gly972→Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. J Clin Invest 104:357–364PubMed
23.
Marchetti P, Lupi R, Federici M et al. (2002) Insulin secretory function is impaired in isolated human islets carrying the Gly(972)→Arg IRS-1 polymorphism. Diabetes 51:1419–1424
24.
Xuan S, Kitamura T, Nakae J et al. (2002) Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 110:1011–1019CrossRefPubMed
25.
Férnandez AM, Kim JK, Yakar S et al. (2001) Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926–1934CrossRefPubMed
26.
Dey BR, Furlanetto RW, Nissley SP (1998) Cloning of human p55 gamma, a regulatory subunit of phosphatidylinositol 3-kinase, by a yeast two-hybrid library screen with the insulin-like growth factor-I receptor. Gene 209:175–183CrossRefPubMed
27.
Shepherd PR, Kahn BB (1999) Glucose transporters and insulin action—implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248–257PubMed
28.
Terauchi Y, Tsuji Y, Satoh S et al. (1999) Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet 21:230–235PubMed
29.
Baier LJ, Wiedrich C, Hanson RL, Bogardus C (1998) Variant in the regulatory subunit of phosphatidylinositol 3-kinase (p85alpha): preliminary evidence indicates a potential role of this variant in the acute insulin response and type 2 diabetes in Pima women. Diabetes 47:973–975PubMed
30.
Hansen T, Andersen CB, Echwald SM et al. (1997) Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index. Diabetes 46:494–501PubMed
31.
Hansen L, Zethelius B, Berglund L et al. (2001) In vitro and in vivo studies of a naturally occurring variant of the human p85alpha regulatory subunit of the phosphoinositide 3-kinase: inhibition of protein kinase B and relationships with type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity. Diabetes 50:690–693PubMed
32.
Tuomilehto J, Lindström J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350
33.
Eriksson J, Lindström J, Valle T et al. (1999) Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 42:793–801
34.
World Health Organization (1985) Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 727:1–113PubMed
35.
Laakso M, Malkki M, Kekäläinen P, Kuusisto J, Deeb SS (1994) Insulin receptor substrate-1 variants in non-insulin-dependent diabetes. J Clin Invest 94:1141–1146PubMed
36.
Goldstein BJ (2002) Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90:3G–10GCrossRefPubMed
37.
Lindi V, Uusitupa M, Lindström J et al.(2002) Association of the Pro12Ala polymorphism in the PPAR-gamma 2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51:2581–2586
38.
Rasmussen SK, Lautier C, Hansen L et al. (2000) Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. J Clin Endocrinol Metab 85:1606–1610CrossRefPubMed
Metadata
Title
Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes.
The Finnish Diabetes Prevention Study
Authors
O. Laukkanen
J. Pihlajamäki
J. Lindström
J. Eriksson
T. T. Valle
H. Hämäläinen
P. Ilanne-Parikka
S. Keinänen-Kiukaanniemi
J. Tuomilehto
M. Uusitupa
M. Laakso
for the Finnish Diabetes Prevention Study Group
Publication date
01-05-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1395-6

Other articles of this Issue 5/2004

Diabetologia 5/2004 Go to the issue

Review

Control of glycaemia: from molecules to men. Minkowski Lecture 2003

Article

Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans

Article

Temporal changes in prevalence of diabetes and impaired glucose tolerance associated with lifestyle transition occurring in the rural population in India

Article

Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of Type 2 diabetic patients

Article

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

Article

Abnormal splicing of hepatocyte nuclear factor-1 beta in the renal cysts and diabetes syndrome
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits